Success for combination Zelboraf + cobimetinib in Advanced Melanoma - Genentech/Roche
Genentech, a member of the Roche Group announced positive data from the coBRIM Phase III study. The results showed that people with previously untreated BRAF V600 mutation-positive Advanced Melanoma who received the MEK inhibitor cobimetinib plus Zelboraf (vemurafenib) lived significantly longer without their disease worsening or death (progression-free survival; PFS) compared to Zelboraf alone.
The combined therapy reduced the risk of disease worsening or death by half (hazard ratio [HR]=0.51, 95 percent confidence interval [CI] 0.39-0.68; p<0.0001), with a median pfs of 9.9 months for cobimetinib plus zelboraf compared to 6.2 months with zelboraf alone. the safety profile was consistent with a previous study of the combination. the most common adverse events seen in the combination arm included diarrhea, nausea, rash, photosensitivity and lab abnormalities.>0.0001),>
The study was published online in the New England Journal of Medicine.
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).